Most affinity-maturation campaigns for antibodies and T-cell receptors (TCRs) operate on the residues at the binding site, located within the loops known as complementarity-determining regions (CDRs). Accordingly, mutations in contact residues, or so-called "second shell" residues, that increase affinity are typically identified by directed evolution involving combinatorial libraries. To determine the impact of residues located at a distance from the binding site, here we used single-codon libraries of both CDR and non-CDR residues to generate a deep mutational scan of a human TCR against the cancer antigen MART-1⅐HLA-A2. Non-CDR residues included those at the interface of the TCR variable domains (V␣ and V␤) and surface-exposed framework residues. Mutational analyses showed that both V␣/V␤ interface and CDR residues were important in maintaining binding to MART-1⅐HLA-A2, probably due to either structural requirements for proper V␣/V␤ association or direct contact with the ligand. More surprisingly, many V␣/V␤ interface substitutions yielded improved binding to MART-1⅐HLA-A2. To further explore this finding, we constructed interface libraries and selected them for improved stability or affinity. Among the variants identified, one conservative substitution (F45␤Y) was most prevalent. Further analysis of F45␤Y showed that it enhanced thermostability and increased affinity by 60-fold. Thus, introducing a single hydroxyl group at the V␣/V␤ interface, at a significant distance from the TCR⅐peptide⅐MHCbinding site, remarkably affected ligand binding. The variant retained a high degree of specificity for MART-1⅐HLA-A2, indicating that our approach provides a general strategy for engineering improvements in either soluble or cell-based TCRs for therapeutic purposes. . 2 The abbreviations used are: TCR, T-cell receptor; V␣, variable region of ␣ chain of TCR; V␤, variable region of ␤ chain of TCR; CDR, complementaritydetermining region; FR, framework region; scTCR, single chain T-cell receptor; pep⅐MHC, peptide complexed with major histocompatibility complex; HLA, human leukocyte antigen (refers to human major histocompatibility complex alleles)
The two major classes of antigen receptors in the immune system, antibodies and T-cell receptors (TCRs), 2 are het-erodimers that recognize their antigens through the action of six hypervariable loops called complementarity-determining regions (CDRs). Three of the CDRs are encoded by the variable region domain of one chain, and three of the CDRs are encoded by the variable region domain of the other chain. The affinity of antibodies can be increased naturally by B cells through a process of somatic hypermutation (1-3) that focuses on the V regions. In contrast, T cells do not contain the machinery for hypermutation, and their receptors are thus of low affinity (4 -6) .
In the case of antibodies and TCRs, it is now possible to affinity-mature their binding sites in vitro using the process of directed evolution (2, 7, 8) . This process has typically involved the generation and selection of large libraries of CDR mutants in a system such as phage, ribosome, or yeast display. In the early 1990s, Winter and colleagues (9, 10) displayed naive as well as synthetic human antibody repertoires on the surface of phage that could be selected with different antigens to obtain desired antigen specificities and to use in vitro affinity maturation of antibodies with affinities in the low nanomolar range (11) . In the same decade, ribosome, phage, and yeast display were also developed to improve the affinity of antibodies (12) (13) (14) (15) . At the same time, the yeast-display system was used to engineer stabilized single-chain mutants of the TCR 2C (16) and subsequently to isolate higher affinity mutants of the 2C TCR by generating libraries in CDR residues, followed by selection with the peptide⅐major histocompatibility complex (pep⅐MHC) ligands (17) (18) (19) . Other TCRs have been engineered for high affinity against their pep⅐MHC ligands (20 -23) , and more recently we created new specificities using directed evolution of the human TCR A6 (24).
An additional challenge in the field of antibody and soluble TCR engineering has been to improve their stability and yields for use in therapeutic applications. One approach to this problem has been to design mutations that promote preferential pairing of antibody heavy and light chains, or TCR ␣ and ␤ chains. For example, the "knobs in hole" concept of Carter and colleagues (25) (26) (27) has been used to generate more stable antibodies or to drive the pairing of the appropriate chains in the production of bispecific antibodies. Similarly, two cysteines have been engineered into the constant regions of the TCR ␣ and ␤ chains to stabilize the extracellular domains in soluble form or as a cell-surface heterodimer (28, 29) . In addition to directed evolution as a strategy to improve binding affinity, we have used the method to generate improved stability of TCR variable domains by selection of libraries of mutants throughout the V region using Escherichia coli mutator strains or errorprone PCR (16, 22, 30 -34) . Selection for stabilizing mutations was made possible by the observation that higher stability was associated with higher levels of display on yeast (16, 30) . Mutations engineered through this process can act in multiple different mechanisms (e.g. through substitutions of exposed surface residues or the interface residues between V regions) (16, 30, 35) . The strategies that have allowed for selection of stable variants of a protein have often used increasing temperatures as a selection pressure in the screening of yeast libraries for thermostable variants (36) .
More recently, we used deep mutational scans (37) (38) (39) of TCRs to understand the role of CDR residues in binding and stability (40, 41) . Single-codon libraries (SCLs) in all of the CDRs in TCRs against the viral antigen Tax⅐HLA-A2 and the cancer antigen MART-1⅐HLA-A2 were generated, and selections with peptide⅐HLA-A2 revealed the sequence fitness landscape for these TCRs (40) . In addition, the approach showed that ϳ8% of the CDR substitutions yielded enhanced binding or stability. The combination of CDR mutations that individually yielded modest improvements in binding allowed the identification of TCR mutants that were 100-fold higher affinity, on par with directed evolution strategies (41) .
Using both deep mutational scans and directed evolution, here we examined another human TCR against MART-1⅐HLA-A2, called T1, with a goal of determining whether V region interfaces could be engineered for greater stability and expression properties. Single-codon libraries were generated in both CDR and non-CDR residues, including framework residues located at the V␣/V␤ interface, and the yeast-displayed libraries were selected with the antigen. Unexpectedly, numerous mutants were identified from the sequence fitness landscape where a substitution at the V␣/V␤ interface yielded enrichment, similar to the number found in CDRs, a finding that could be due to higher yeast surface levels (e.g. due to improved stability) or higher affinity.
Based on these results and the known structures of TCRs, we generated dual-codon libraries of opposing pairs of interface residues and subjected these and the single-codon libraries to antigen selection by high-speed flow sorting. Independent isolates identified from these selections revealed a predominant interface mutant, F45␤Y. Remarkably, this subtle substitution not only showed enhanced surface display but exhibited a 50-fold improvement in affinity (K D ϭ 2 nM) in yeast-display experiments. The soluble, refolded TCR also exhibited a 60-fold increase in affinity and an increase in thermal stability. The F45␤Y mutant retained specificity for MART-1⅐HLA-A2, as it did not bind to other peptide⅐HLA-A2 complexes. These results demonstrate that subtle changes at the interface that are outside the antigen-binding site can operate at a distance to modulate binding site residues. In addition, they suggest that V␣/V␤ interface substitutions should be included in efforts to identify TCRs with affinity and stability improvements for use as soluble therapeutics or in adoptive T-cell therapies.
Results

Deep mutational scan of a single-chain (V␤-linker-V␣) human TCR
A TCR isolated from the human T-cell clone called INR1-T1, specific for MART-1⅐HLA-A2, was engineered previously as a single-chain TCR (scTCR) (V␤16-linker-V␣2; TRBV30-linker-TRAV12-2 in IMGT nomenclature) by identifying mutations that enabled yeast surface display and expression as a soluble protein (23) . This TCR is referred to as T1-WT here (Fig. S1 ). Sorting CDR libraries of the T1-WT scTCR yielded a mutant called T1-S18.45 that exhibited 710-fold higher affinity (K D of 45 nM) than the wildtype affinity (K D of 32 M) (23) . Because the T1-S18.45 mutant TCR (called T1 from here on) has sufficient affinity to perform binding selections by yeast display, it was used to conduct a deep mutational scan of all CDR residues and many framework residues by generating SCLs (Fig. S1 ). The framework residues focused in particular on those located at the interface of V␣ and V␤ domains so that we could determine whether the wildtype residues have been optimally selected, presumably by evolution or by processes involved in thymic development, for the interaction of the two domains. The issue for V␤ domain associations as dimers is even more complicated, as there are models suggesting that during thymic development, the V␤ domain of the rearranged ␤ chain in the pre-TCR could interact either with the invariant ␣ chain (pT␣) or with residues in a second V␤ to form a dimer (42) .
The SCL included 45 residues in the V␣ and 42 residues in the V␤ ( Fig. 1 and Fig. S1 ). Of the 87 positions, 43 were located in the predicted CDRs (21 residues in the V␣ and 22 residues in V␤). To determine which residues are likely to be located at the V␣/V␤ interface, we relied on the structures of known TCRs, in particular four TCRs that all contained the same V␣ region (TRAV12-2, also known as V␣2): Mel5 (PDB code 3HG1), DMF5 (PDB code 3QDG), RD1-MART1 HIGH (PDB code 5E9D), and A6 (PDB code 1AO7) (40, (43) (44) (45) . This analysis identified 15 residues at the interface in the V␣ and 16 residues at the interface in the V␤. As an additional control, we constructed 13 SCLs in residues of surface framework regions (surface FR) that were predicted to be in surface-exposed positions but were distal to the pep⅐MHC-binding site ( Fig. 1 and Fig. S1 ). 
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SCLs were constructed as described previously (41) , and pooled libraries were transformed into yeast cells. The libraries were analyzed in comparison with the parental TCR T1 for binding to monomeric MART-1⅐HLA-A2 and tetrameric MART-1⅐HLA-A2 ( Fig. 2 ). As expected, compared with the parental T1 TCR, the pooled SCL exhibited a reduction in binding indicative of a significant fraction of substitutions that lowered or eliminated binding to the ligands.
Based on the binding curves for the SCL and our previous experience with yeast selections in deep mutational scans, we chose to sort the libraries with 10 nM monomeric ligand (MART-1⅐HLA-A2), a concentration that was ϳ5-fold lower than the K D determined previously by surface plasmon resonance (23) . We collected the top 1% of yeast cells with bound ligand, expanded them, isolated plasmid DNA, and subjected it to deep sequencing. DNA from the unselected SCL was also subjected to deep sequencing, and enrichment ratios for every substitution at each targeted residue were calculated relative to the unselected libraries and plotted on a log 2 scale. The analysis allowed the generation of a sequence fitness landscape with a color-coded scale ( Fig. 3 ) as follows: blue (enriched compared with unselected library), orange (depleted compared with unselected library), and white (at the same frequency as in the unselected library). By way of example, in the log 2 scale, an enrichment ratio of 5 corresponds to 2 5 or a 32-fold higher number of transcripts (for the enriched (blue) substitution compared with wildtype), whereas an enrichment ratio of Ϫ3 corresponds to 2 Ϫ3 or an 8-fold lower number of transcripts (for the depleted (orange) substitution compared with wildtype). As observed in our previous sequence fitness landscapes, the majority of substitutions have a negative impact on ligand binding, because the folding, aggregation, and structural integrity of the V domains, in addition to ligand binding, are all sensitive to selection with the MART1⅐HLA-A2 probe.
To gain a more quantitative assessment of the impact of individual CDR loops or framework regions, we averaged the enrichment values for every substitution within the six CDRs, the two interface regions, or the two surface-exposed framework regions (Fig. 4A, red bars) . The results for the surface FR opposite the binding site represent the basal impact of substitutions on the folding, aggregation, and stability of the singlechain TCR, all involved in export and display on the surface. For example, changes of surface hydrophilic residues to hydropho-bic residues would be expected to have a negative impact. Hence, substitutions of the surface FR regions show a significant impact on selection but exhibit the lowest average enhancement values compared with the other regions (see red bars in Fig. 4A ). Conversely, residues in CDR3␣ in T1, followed by CDR3␤, had the overall greatest impact of substitutions, suggesting that they play a key role in MART-1⅐HLA-A2 binding ( Fig. 4A ). This was consistent with our previous deep mutational scan of two other V␣2-containing TCRs (RD1-MART1 HIGH and A6-c134), where most substitutions in these regions were also depleted (40) . The degree of tolerance of substitutions in T1 CDRs allowed us to rank the importance of each CDR in ligand binding as follows: CDR3␣ Ͼ CDR3␤ Ͼ CDR2␣ Ͼ CDR2␤ Ͼ CDR1␣ Ͼ CDR1␤ ( Fig. 4A ). Most substitutions in the V␣/V␤ interface were also depleted to a similar degree as in the CDRs, indicating that many substitutions destabilize the V␣/V␤ interaction ( Fig. 4A ).
As previously noted in our deep mutational scans of two other TCRs (40, 41) , a significant number of CDR substitutions were enriched (i.e. blue) in T1 relative to the wildtype amino acids (Figs. 3 and 4B). For example, transcripts with the following substitutions were enriched 8-fold or more compared with wildtype: D26␣P, G28␣S/H/F/Y/M, S31␣G/A, S51␣G/A, S91␣A, I26␤G/L, S27␤P, H29␤M, D30␤E, N31␤H, K51␤Q, S53␤W/L, and A97␤T. Although CDR3␣ and CDR3␤ are positioned directly above the peptide in TCR⅐pep⅐MHC structures, enriched substitutions in T1 were distributed across all CDRs, indicating that they may act to optimize the interaction with MART-1⅐HLA-A2 either by direct contact or by inducing conformational changes that configure the contact residues in more optimal positions. Although we have observed such enhancing substitutions in the CDRs of a different TCR previously (41), we were particularly surprised that the V␣/V␤ interface also contained numerous substitutions that were enriched the T1 TCR, it appears that X can be favorably substituted by almost any amino acid (Fig. 3) . The enrichment observed for many interface substitutions suggests that there are significant opportunities to engineer more stable V␣/V␤ interactions by directed evolution.
Stability scans of the TCR single-codon libraries
As indicated, enrichment of mutants with a particular substitution in yeast-display selections of single-codon libraries can be due to an increase in stability (surface level) or affinity of the mutant (41) . Surface levels of expressed proteins have been associated with the stability of the properly folded protein (30, 31, 46) . To understand whether enrichment of mutants with some of the substitutions might have been due to increased stability, we decided to conduct several additional screens, followed by deep sequencing. First, we used a relatively high concentration of tetrameric MART-1⅐HLA-A2 (tetramer) (100 nM) that would in principle be more sensitive to surface levels than to the intrinsic affinity of the TCR (albeit still dependent on binding). In addition, we used the tetramer to select SCLs that were exposed to a higher temperature (45°C for 30 min), thus enriching for the most stable TCRs (31) . Finally, we used an anti-V␤16 monoclonal antibody, which should not require a V␣-specific epitope but does require proper conformation of the protein because the antibody binds to native V␤16 ϩ TCRs on the cell surface.
Sequence fitness landscapes for each selection are shown in Figs. S2 and S3 and Fig. 5 . The overall pattern of enrichment of residues in tetramer-selected SCLs, whether exposed to the 
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higher temperature or not, was almost identical (Figs. S2 and S3). The identical profiles were most likely due to the already relatively high thermostability of the template T1 (see below (Fig. 9 , D and E)), in part based on the stability of the V␣2 domain (47) . The similarity in pattern of enrichment between the two selections was most apparent when plotting the enrichment value for each substitution selected with tetramer versus the enrichment value for the same substitution selected with "heat ϩ tetramer" condition. Our previous deep mutational scans have shown that duplicate selection with the same ligands yield correlation (R 2 ) values that are Ͼ0.8 in the positive enrichment substitutions (blue) and correlations in the range of 0.5 in the negative enrichment substitutions (orange) (40) . Overall correlation plots for the tetramer selections yielded R 2 values in the range of 0.45-0.65 (Fig. 6A ), indicative of good correlations and substantiating the reproducibility of the deep mutational scan method (40) . Whereas substitutions in CDRs, interface, and surface FR of V␣ demonstrated good correlation (i.e. enriched or depleted to similar levels), substitutions in surface FR of V␤ exhibited poorer correlation in part due to their relatively smaller sample size and the lower level of their negative enrichment values.
The patterns of enrichment for the monomer selection ( Fig.  3 ) and tetramer selections (Figs. S2 and S3) were also similar, although in general, the magnitude of enrichment values was overall reduced in the tetramer data set ( Fig. 4A ), leading to lower average correlation values between the two selection schemes (R 2 in the range 0.23-0.46) ( Fig. 6B ). Because both monomeric and tetrameric MART-1⅐HLA-A2 interact with the same binding site on the TCR, the differences are probably due to the impact of surface levels and hence stability. Nevertheless, the hierarchy of enhancement values for each CDR and framework region remained the same with the two selections ( Fig.  6B ). Interestingly, although most surface framework residues and many CDR residues appeared to have reduced impact compared with the monomer selection (i.e. values closer to 0), many interface substitutions retained their level of impact on enrichment or depletion. Accordingly, scatter plots indicated that there were typically higher correlations between enrichment/ depletion of substitutions in interface residues ( Fig. 6B ) than in CDR residues. Whereas residues in surface FR of V␣ were enriched or depleted to similar levels (R 2 ϭ 0.46), substitutions in certain surface FR of V␤ were preferentially enriched with monomer selection compared with tetramer, hence leading to lower correlation (R 2 ϭ 0.09). As mentioned above, these substitutions may have allowed for improved stability of V␤ and hence expression of the TCR on yeast surface rather than having an impact on binding affinity.
Selection with the anti-V␤16 antibody ( Fig. 5 ) provides information about the TCR using a probe that is completely different from the MART-1⅐HLA-A2 ligand ( Fig. 3 and Figs. S2 and S3). Although the specific epitope of this antibody has not been identified, it binds only to T cells with a V␤16 ϩ TCR, and hence it binds to epitopes found on all V␤16 domains (48) . This excludes epitopes on V␣ and those generated by the CDR3␤ loop, both of which vary among V␤16 ϩ T cells. Consistent with these expectations, examination of the anti-V␤16 sequence fitness landscape ( Fig. 5 ) showed overall less impact of V␣ CDRs and V␣ surface FR residues compared with monomer or tetramer selections (Fig. 4A ). However, the V␤ CDRs also appeared to show less impact on anti-V␤16 antibody binding than the MART-1⅐HLA-A2 ligand, suggesting that the epitope does not reside in the CDR1␤ or CDR2␤. In contrast, substitutions of the surface-exposed residues of the V␤ framework ( Fig.  1 ) were substantially depleted with the anti-V␤16 antibody in contrast to selections with the MART-1⅐HLA-A2 ligand (Figs. 3B, 4A, and 5B). This finding was consistent with the lower correlation in this region between the selections with different ligands (R 2 ϭ 0.1 in Fig. 6C and Fig. S4 ). We propose that this observation is consistent with this region comprising a part of the anti-V␤16 epitope (Fig. S5 ). This possibility is supported by analysis of all human V␤ sequences, showing that this stretch of amino acids ( 59 GMPN 62 ) is unique to V␤16 among all 60 V␤ genes. Unexpectedly, the anti-V␤16 probe showed that V␣ and V␤ interface residues exhibited a sequence fitness landscape that was similar to that observed in the screens with the MART-1⅐HLA-A2 monomer and tetramer ligands (Figs. 3, 5, and 6C and Fig. S4 ). This result suggests that although the epitope does not reside in V␣, these V␣ and V␤ interface residues are necessary for proper conformation of the V␤ domain. This observation is also consistent with the finding that stop codons in the V␣ region were negatively selected, although the protein is cloned as a V␤-linker-V␣ construct. Screens of TCRs with different V␤ in yeast display using other anti-V␤ antibodies have shown no need for the V␣ domain in the yeast-display format, or even enhanced surface levels when a stop codon was introduced into the V␣ (32, 34, 49, 50) . It is possible that the finding here with the anti-V␤16 antibody reflects the unique structural requirements for the epitope of this antibody, compared with the other anti-V␤ antibodies. When comparing enrichment or depletion of substitutions in CDR residues when T1-SCL was selected with two different ligands (monomeric or tetrameric MART-1⅐HLA-A2 versus anti-V␤16), lower R 2 values (R 2 ϭ 0.1-0.2) indicated the requirement of unique substitutions for interacting with each ligand as expected ( Fig. 6C and Fig. S4 ). However, as indicated, substitutions in interface residues exhibited better correlations (R 2 ϭ 0.2-0.5).
Interface libraries guided by sequence fitness landscapes lead to isolation of stable, high-affinity mutants
To further assess the extent to which V␣/V␤ interface residues could impact stability and/or pep⅐MHC affinity, we took a directed evolution approach that used existing SCLs in inter- 
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face residues (Phe 33␣ , Lys 41␣ , Ser 42␣ , Met 97␣ , Asp 100␣ , Met 39␤ , Lys 41␤ , Glu 42␤ , Lys 44␤ , Phe 45␤ , Met 60␤ , Phe 91␤ , Val 101␤ , Glu 102␤ , and Gly 106␤ ) and additional, paired-codon libraries (PCLs) generated in interface residues. The choice of positions to randomize at the V␣/V␤ interface was based on the enrichment results of the deep mutational scan, together with an analysis of the structures of known TCRs (40, (43) (44) (45) to identify possible paired residues across the V␣/V␤ interface. For the latter, each interface residue was used to search for a possible binding partner in the opposing domain (within a 4-Å space). Accordingly, PCLs (Fig. S1 ) were constructed using PCR splicing by overlap extension in the following residues: Lys 41␤ -Asp 100␣ , Glu 42␤ -Asp 100␣ , Lys 44␤ -Met 97␣ , Phe 45␤ -Met 97␣ , Phe 91␤ -Lys 41␣ , Phe 91␤ -Ser 42␣ , and Gly 106␤ -Ser 42␣ . A mixture of the SCLs and PCLs (referred to as interface libraries hereafter) were sorted twice with 1 nM monomeric MART-1⅐HLA-A2. To be able to screen for improved properties that would allow application of engineered TCRs in adoptive T-cell therapies or as soluble therapeutics in a physiologic setting, we included a sort in which yeast cells were incubated in 100% human serum. For example, exceptional stability in serum could enrich for substitutions that resist proteolysis or other serum-derived enzymes that lead to a reduction in surface levels of the TCRs. In this regard, incubation of the parental T1 TCR in serum yielded reduced staining with MART-1⅐HLA-A2 monomer (Fig. 7A) .
A decrease in binding of the interface libraries to 10 nM MART-1⅐HLA-A2, compared to parental T1 TCR, was observed (Fig. 7, A and B) . This was expected because most V␣/V␤ interface mutations destabilize the TCR (Fig. 2) . The binding was reduced further when analyzed in the presence of serum. However, after two sorts in the presence or absence of serum, the interface libraries exhibited a strong increase in binding to MART-1⅐HLA-A2 (Fig. 7, C and D) . The populations from both selections were able to bind MART-1⅐HLA-A2 at concentrations as low as 100 pM, significantly improved compared with the parental T1 TCR. For example, staining of the sorted population showed higher signal at 100 pM ligand (Fig. 7, C and D) than staining of the parental T1 at 10 nM ligand, a 100-fold higher concentration (Fig. 7A ). 
Ten clones were cultured from the second sort of each condition (1 nM MART-1⅐HLA-A2, with or without serum), and the induced cells were analyzed further for binding to MART-1⅐HLA-A2. Sequences were obtained from 19 clones, and all but one contained the mutation F45␤Y. Sorting in the presence of serum yielded three unique mutants: F45␤Y (7 of 9), F45␤Y/ M97␣R (1 of 9), and F91␤Y (1 of 9). Sorting in the absence of serum yielded six unique mutants: F45␤Y (4 of 10), F45␤Y/ K44␤E (1 of 10), F45␤Y/E102␤R (1 of 10), F45␤Y/D100␣S (1 of 10), F45␤Y/D100␣E (1 of 10), F45␤Y/E102␤K/M97␣E (1 of 10), and F45␤Y/M97␣Q/K41␣A (1 of 10). Interestingly, the deep mutational scan of monomer-sorted T1-SCL had demonstrated 4-fold or higher enrichment for many of these substitutions. The F45␤Y and M97␣Q substitutions were enriched 48and 32-fold, respectively, compared with wildtype residues (Fig.  3) , consistent with their representation in the selected clones.
Because we were interested in obtaining interface mutants that improved the V␣/V␤ interaction, clones that contained mutations in the spatially close Phe 45␤ /Met 97␣ pair were chosen for further analysis (F45␤Y/M97␣R and F45␤Y/M97␣Q/ K41␣A). In addition, the single-site F45␤Y mutant and singlesite F91␤Y mutant were analyzed further to assess their behavior as single mutations. Further analysis of these mutants was also based on staining with 100 pM MART-1⅐HLA-A2 (data not shown) and enrichment scores of individual mutations from monomeric MART-1⅐HLA-A2 selection of T1-SCL. The four unique mutants (F45␤Y, F91␤Y, F45␤Y/M97␣R, and F45␤Y/ M97␣Q/K41␣A) were analyzed by flow cytometry-based ligand titrations with monomeric MART-1⅐HLA-A2. Surprisingly, the mutants F45␤Y, F45␤Y/M97␣R, and F45␤Y/ M97␣Q/K41␣A not only exhibited higher yeast surface levels (i.e. due to increased stability), but they had K D values in the range of 1.0 -2.3 nM, ϳ50 -100-fold higher affinity than the parental T1 TCR and mutant F91␤Y ( Fig. 8A and Table 1 ). This result suggested that the mutation in common among them (F45␤Y) accounted for the majority of the affinity increase. Similarly, the F45␤Y mutation also appeared to be responsible for higher surface display levels compared with the T1 TCR (Fig. 8A) .
The unexpected magnitude of the affinity increase (that is, ϳ50-fold higher compared to T1 TCR) with the interface mutation F45␤Y raised the question of whether the mutants would retain specificity for the MART-1 peptide, or the mutation might have enabled binding to other peptide⅐HLA-A2 complexes, perhaps by enhanced interactions with the HLA-A2 helices. To test this, we examined binding of the T1 TCR and all four mutants to a high concentration of tetramers generated with a panel of HLA-A2-restricted cancer or virus peptides (Fig. 8B) . Although all of the TCRs bound strongly to the MART-1⅐HLA-A2 tetramers, none of the eight other complexes tested bound to the interface mutants or the T1 TCR. Thus, the increase in affinity did not result in detectable levels of peptide cross-reactivity, even with multivalent reagents that are capable of detection when the monomeric K D values are in the micromolar range (51) .
Affinity of soluble mutant TCR F45␤Y
To show that the affinity and stability improvements associated with the interface mutation F45␤Y would be transferred to the soluble form of the TCR (i.e. not found only in the yeastdisplay version), we expressed the T1 and F45␤Y TCRs as inclusion bodies in E. coli and purified by nickel chromatography and gel filtration (SDS-polyacrylamide gel; Fig. 9A, inset) , as we have done with other single-chain TCRs (22, 23, (52) (53) (54) . To compare the binding of the soluble proteins, MART-1⅐HLA-A2 monomeric complexes were titrated on immobilized soluble T1 TCR or F45␤Y TCR, and the bound HLA-A2 was detected with anti-␤2m antibody-HRP conjugates (Fig. 9A ). In this assay, the soluble T1 TCR exhibited a K D value of 76 nM, and the soluble F45␤Y TCR exhibited a K D value of 1.3 nM. Thus, the soluble form recapitulated the effect of the mutation on affinity of the yeast-displayed form.
To determine kinetic parameters of their interaction, we performed a kinetic titration experiment using surface plasmon resonance (SPR) (55) . Biotinylated MART-1⅐HLA-A2 was immobilized on a sensor chip, and various concentrations of soluble, monomeric scTCRs (T1 or F45␤Y) were injected, without regeneration steps between injections. An unrelated peptide⅐HLA-A2 complex (WT1⅐HLA-A2) was immobilized on a reference flow cell to control for nonspecific binding. The association and dissociation phases were monitored for 2 and 3 min, respectively. SPR measurements indicated that the F45␤Y TCR exhibited ϳ58-fold increase in affinity (K D of 0.26 nM), compared with the T1 TCR (K D of 15.2 nM) with faster on-rate and slower off-rate kinetics (Fig. 9, B and C) .
Thermal stability of T1 and F45␤Y TCRs
As indicated above, the yeast-displayed F45␤Y TCR exhibited a higher maximal cell-surface level than the T1 TCR (Fig.  8A) , a property that has been shown previously to correlate with increased thermal stability (30, 46) . To examine the thermal stabilities of the T1 TCR and F45␤Y TCR, we took two inde- 
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pendent approaches. In one approach, we used differential scanning fluorimetry (DSF) to measure the stability of the soluble proteins (56) . The soluble TCRs were incubated with SyproOrange, and fluorescence was monitored at increasing temperature (25-100°C at a 1°C/min ramp rate) in a real-time thermal cycler. Corresponding fluorescence profiles ( Fig. 9D ) and first derivative curves (Fig. 9D, inset) allowed us to determine melting temperature (T m ) values for each protein. The T1 TCR had a T m value of 42.4 Ϯ 0.3°C, whereas the F45␤Y TCR had a T m value of 48.8 Ϯ 0.3°C. Thus, the single interface mutation F45␤Y resulted in ϳ6°C higher temperature stability.
We also compared the temperature stability of yeast-displayed TCRs by a flow cytometry-based irreversible thermal denaturation assay (46) . In this assay, cells were incubated at temperatures ranging from 30 to 80°C for 30 min and then stained with monomeric MART-1⅐HLA-A2 ligand (Fig. 9E) . The resulting temperature denaturation curves indicated that the T m of F45␤Y (57.5°C) was ϳ6°C higher than the parental T1 TCR (51.5°C), supporting the findings with DSF. The T m of the parental TCR explains why the addition of a 45°C temperature step in the tetramer selection did not differ substantially from the tetramer-only selection.
Impact of F45␤Y mutation on low-affinity T1-WT TCR
To assess whether the F45␤Y mutation would exert a similar effect on another V␣2/V␤16 TCR with phenylalanine at position 45 in the ␤-chain, we introduced the F45␤Y mutation into T1-WT (note that this TCR was engineered for expression on the yeast cell surface, but it retained its low wildtype affinity for MART-1⅐HLA-A2 (K D of 32 M) because it lacked the CDR3␣ mutations present in T1) (23) (Fig. S1 ). Due to the low affinity of T1-WT, we performed flow cytometry-based ligand titrations with tetrameric MART-1⅐HLA-A2 in addition to titrations with monomeric MART-1⅐HLA-A2 (as in Fig. 8A ). Titrations with tetrameric ligand indicated that the F45␤Y mutation increased surface levels in comparison with T1-WT ( Fig. 10A ). As expected, the F45␤Y mutation in the T1 TCR was again expressed at higher levels compared with the T1 TCR ( Figs. 8A  and 10A ). Although the monomeric ligand titrations allowed determination of approximate dissociation constants for the high-affinity T1 and F45␤Y TCRs (Figs. 8A and 10B, inset) , saturation was not reached for the low-affinity T1-WT TCR and T1-WT-F45␤Y mutant (Fig. 10B) . However, the increase in binding to both monomeric and tetrameric MART-1⅐HLA-A2 by the T1-WT-F45␤Y mutant, compared with T1-WT, suggested that the F45␤Y mutation in this TCR also resulted in an increase in affinity.
Discussion
We describe here the results of the most thorough deep mutational scan (37-39, 57, 58) yet conducted with a TCR. The analysis included not only CDR residues, as published recently (40, 41) , but also a large number of framework residues that are located on the surface of the V domains or at the interface of the V␣ and the V␤. As expected, we observed many substitutions in both the CDRs and the interface that were depleted in the pep⅐MHC selections (i.e. orange in Fig. 3 ) because binding would be influenced by both affinity and the presence of properly folded and associated V␣ and V␤ domains. We also observed, as expected based on our previous studies, a smaller frequency of substitutions in CDR residues that yielded improvements in these properties (i.e. blue in Fig. 3 ). However, to our surprise, we saw a similar or higher (depending on set enrichment cutoff) frequency of substitutions in the interface residues that yielded improvements in these properties (Fig.  4B ). Whereas we anticipated these would be exclusively due to stabilization of the V␣/V␤ association, and thus higher yeast surface levels, we discovered by conducting follow-up directed evolution selections that one of the highly enriched substitutions (F45␤Y) was actually acting to increase the affinity by a remarkable 60-fold. Figure 8 . Flow cytometric analysis of V␣/V␤ interface mutants of T1 TCR for binding with peptide⅐HLA-A2 monomers or tetramers. A, yeast-displayed T1 TCR or interface mutants (F91␤Y, F45␤Y/M97␣R, F45␤Y/M97␣Q/K41␣A, and F45␤Y) were stained with varying concentrations of monomeric MART-1⅐HLA-A2 (biotinylated), followed by streptavidin-PE. Resultant MFU were plotted against ligand concentration to obtain dissociation constants for each mutant (listed in Table 1 ). B, peptide specificity of T1 or interface mutants was determined by staining with 50 nM peptide⅐HLA-A2 tetramers prepared with streptavidin-PE. bHLA-A2, biotinylated HLA-A2.
Table 1 Dissociation constants of yeast-displayed T1 or interface mutants by flow cytometry
Yeast-displayed TCRs were titrated with monomeric MART-1⅐HLA-A2, as described in the legend to Fig. 8A . Resulting data were fit to a one-site-specific binding equation (Y ϭ B max ϫ X/(K D ϩ X), where X is ligand concentration, and Y is mean fluorescence units) to obtain K D with GraphPad Prism software. Average K D values from several experiments (n ϭ 7, 1, 2, 2, and 5 for T1, F91␤Y, F45␤Y/M97␣R, F45␤Y/M97␣Q/K41␣A, and F45␤Y, respectively) are reported.
Yeast-displayed TCR
K D nM T1 101 Ϯ 48 F91␤Y 122 Ϯ 29 F45␤Y/M97␣R 2.3 Ϯ 0.3 F45␤Y/M97␣Q/K41␣A 1 Ϯ 0.1 F45␤Y 2 Ϯ 0.5
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The identification of a conservative substitution (Phe to Tyr, adding only a single hydroxyl group) that is able to act at a distance of up to ϳ20 Å from the TCR⅐pep⅐MHC-binding interface to increase the affinity by 60-fold and the temperature stability by 6°C raises the obvious question of mechanism of action. In the absence of a structure for the T1 TCR, we resorted to protein modeling using RosettaBackrub (59) to gain insight into this question. Because the Mel5 TCR (PDB code 3HG1) (43) also binds to MART-1⅐HLA-A2 and uses the same V␣ region (V␣2 or TRAV12-2), we used it as a template for modeling the V␣/V␤ interface of the T1 TCR, with the wildtype Phe or the mutated Tyr at V␤ position 45. Overlay of the top-scoring models suggested that the phenyl ring of Tyr 45␤ might be flipped relative to Phe 45␤ , allowing Tyr 45␤ to engage in polar interactions with Leu 96␣ and Tyr 35␤ (Fig. 11 ). Although this might explain an improved ability of the V␤ to associate with the V␣ (and thus improve the temperature stability and yeast surface levels), it does not suggest how this interaction could be propagated to the pep⅐MHC-binding site consisting of CDRs, allowing the TCR to bind with 60-fold higher affinity yet maintain peptide specificity.
There may be some precedence for similar long-range effects in the V␤ of a TCR, as we have shown that a V␤ domain engineered for high affinity against the toxin TSST-1 showed cooperativity between two residues that were separated by Ͼ20 Å (60). The mechanism involved in that system remains speculative, but it was suggested to involve a conformational dynamic process propagated along ␤ strand cЉ of the V␤. Analogous allosteric mechanisms have been suggested in TCR/CD3 and TCR/peptide/MHC interactions (61) (62) (63) . Of course, beyond TCR-related systems, there are many other proteins where allosteric effects have been observed at significant distances (e.g. see Refs. 64 -68) . We presume that a similar mechanism is operating with the Tyr 45␤ . Interestingly, the importance of tyrosine residues at protein-protein interfaces has been demonstrated in minimalist combinatorial libraries using only Ser/ Tyr residues, which allow high-affinity interaction with the target by providing a larger interaction interface and mediating more molecular contacts (69, 70) . It is possible that the Tyr 45␤ in T1 allows a more favorable interaction with V␣ due to this effect, but how this drives an increase in affinity for MART-1⅐HLA-A2, presumably by allosteric means, remains unknown. A, T1 and F45␤Y were cloned with N-terminal His 6 tag in pET28a for expression in E. coli. F45␤Y contained additional C-terminal Avitag sequence, hence leading to slight difference in mobility on a 4 -20% SDS-PAGE (inset). Binding of each protein to MART-1⅐HLA-A2 was assessed by detecting the ␤2m subunit of HLA-A2 by ELISA. B and C, kinetic titration to determine dissociation constants of soluble T1 (B) and interface mutant F45␤Y (C) toward MART-1⅐HLA-A2 by surface plasmon resonance. Biotinylated MART-1⅐HLA-A2 was coated on a SPR sensor chip, followed by injection of soluble TCRs over the coated surface. The association and dissociation phases were monitored for 2 and 3 min, respectively. Resulting response was plotted against time, and data were fitted and analyzed using Biaevaluation version 4.1 software. D, DSF profiles of soluble scTCRs (mixed with SyproOrange) when exposed to increasing temperature. Melting temperature can be determined as temperature where half-maximal increase in fluorescence is noted. First derivative curves of DSF data (temperature (T) versus derivative (ѨF/ѨT)) to calculate precise T m values are also shown (inset). E, thermostability of yeast-displayed scTCRs was assessed by exposing yeast cells to temperatures ranging from 30 to 80°C for 30 min, followed by staining with saturating concentration of monomeric MART-1⅐HLA-A2. The percentage decrease in binding (MFU) was calculated relative to binding at 30°C and plotted against temperature to obtain T m .
Unlike most scFv fragments derived from the V L and V H domains of antibodies, single-chain TCRs consisting of V␣ and V␤ domains are not sufficiently stable to allow expression on the yeast surface or in soluble form (35, 46) . Previously, we used error-prone PCR-based methods to stabilize the V domains of a TCR, allowing them to be displayed in a single-chain format on yeast or expressed in soluble form (22, 23, 31, 71) . Among the classes of mutations that allowed higher surface levels were those that resided at the interface of the V␣ and V␤ domains (16, 35) or were distributed elsewhere in the framework region of V domains (22, 30, 31, 34) that endowed higher thermostability. However, these mutations had not been associated with an increase in the affinity of the TCR for the ligand, perhaps because the selecting agent in these stability studies had not Figure 10 . Impact of the F45␤Y mutation on the lower affinity T1-WT TCR. A, yeast-displayed T1 TCR, F45␤Y mutant, T1-WT TCR, and T1-WT-F45␤Y mutant were stained with varying concentrations of tetrameric MART-1⅐HLA-A2 prepared with streptavidin-PE. Resultant MFU were plotted against ligand concentration to obtain binding curves. B, yeast-displayed T1 TCR, F45␤Y mutant, T1-WT TCR, and T1-WT-F45␤Y mutant were stained with varying concentrations of monomeric MART-1⅐HLA-A2 (biotinylated), followed by streptavidin-PE. Resultant MFU were plotted against ligand concentration to obtain binding curves. Binding curves of T1 and F45␤Y are shown in the inset. Figure 11 . Structures of T1 and F45␤Y mutant TCR modeled by RosettaBackrub. A, selected residues at the V␣/V␤ interface in Mel5 TCR (PDB code 3HG1) were mutated to residues in T1 or F45␤Y (Fig. S1 ). Using the RosettaBackrub server (http://kortemmelab.ucsf.edu/backrub), 3 models were generated. Overlaid models of T1 (V␣ (yellow) and V␤ (cyan)) and F45␤Y (V␣ (red) and V␤ (blue)) are shown. MART-1 (green) is shown in complex with HLA-A2 (gray 
been the ligand but was an antibody to the folded V␤ domain. This suggestion is consistent with the deep mutational scan performed here with the anti-V␤16 antibody as the selecting agent. Whereas there were substitutions that yielded enrichments in substitutions in T1 TCR with anti-V␤16 (blue in Fig.  5 ), the F45␤Y substitution, identified here as being highly enriched with MART-1⅐HLA-A2, was not one of them. In contrast, all three deep mutational scans using MART-1⅐HLA-A2 selections had identified the F45␤Y substitution among those having the most significant enhancement values ( Fig. 3 and Figs. S2 and S3 ). Interestingly, it has been demonstrated that framework mutations in anti-HIV-1 antibodies are required for broad neutralization of HIV-1 strains. Specifically, a framework mutation A61P (in the V H domain) caused a decrease in thermal stability of the anti-HIV-1 antibody, but it resulted in an increased flexibility of the framework, thus promoting neutralization of several strains of HIV-1 (72) .
Efforts to engineer higher affinity antibodies and TCRs have typically relied on the use of directed evolution, made possible by generating libraries of mutants in CDRs, the regions involved in antigen binding. The results here show that it is worth considering the generation of libraries at interfaces, which provide opportunities to increase both the stability and affinity of the proteins. In the case of TCRs, these engineered mutants could be valuable as bispecific agents for soluble therapy directed to cancer HLA antigens (21) or in adoptive T-cell strategies (73) .
Experimental procedures
Yeast display, reagents, and flow cytometry
MART-1 (ELAGIGILTV)⅐HLA-A2-specific T1 TCR was expressed in single-chain format (V␤16-linker-V␣2) in yeastdisplay vector pCT302 and engineered for high affinity (23) . Site-directed mutation in T1-WT TCR was generated at position 45 in the ␤-chain using the QuikChange Lightning kit (Agilent Technologies) as described by the manufacturer. For binding experiments, HLA-A2 heavy chain was expressed in E. coli as inclusion bodies and refolded in the presence of human ␤ 2 -microglobulin and UV-cleavable peptide, KILGFVFJV (where J is 3-amino-3-(2-nitro)phenyl-propionic acid) (74) . MART-1⅐HLA-A2 monomers were prepared by UV-mediated peptide exchange. Because HLA-A2 heavy chain was expressed with a C-terminal BirA biotinylation substrate sequence, biotinylated peptide⅐HLA-A2 complexes could be detected with streptavidin-phycoerythrin (streptavidin-PE) (BD Pharmingen). Tetrameric MART-1⅐HLA-A2 was prepared by mixing biotinylated monomer with streptavidin-PE in a 4:1 molar ratio. MART-1 and UV-cleavable peptides were synthesized by GenScript Inc.
To assess binding by flow cytometry, yeast cells displaying T1 TCR (or its libraries or mutants) were stained with various concentrations of biotinylated, monomeric MART-1⅐HLA-A2. After washing, bound biotinylated MART-1⅐HLA-A2 was detected by staining with streptavidin-PE (1:100). In certain experiments, yeast cells expressing T1 TCR (or its libraries or mutants) were incubated in pooled normal human serum (Innovative Research) supplemented with 10 mM EDTA at 37°C for 30 min before staining with monomeric MART-1⅐HLA-2. In some experiments, MART-1⅐HLA-A2 streptavidin-PE tetramers or anti-V␤16 monoclonal antibody (clone TAMAYA1.2, Beckman-Coulter) were used to stain yeast cells. The anti-V␤ antibody was used at a 1:100 dilution followed by goat anti-mouse IgG (HϩL), F(abЈ)2, Alexa Fluor 647 conjugate (1:100) (Life Technologies, Inc.).
Construction, selection, and deep sequencing of single-codon libraries in T1 TCR
SCLs in T1 scTCR were constructed by PCR as described previously (40) . Primers containing a single degenerate codon (NNK) at targeted locations were synthesized by Integrated DNA Technologies and used to create PCR products with degeneracy in one codon at a time via splice overlap extension PCR. Overall, 87 such PCR products were prepared and were pooled and transformed into the EBY100 strain of Saccharomyces cerevisiae, along with digested pCT302 vector to allow construction of SCLs by homologous recombination. Resultant libraries in yeast contained 3.4 ϫ 10 8 independent transformants, which exceeded by several orders of magnitude the expected diversity (87 positions ϫ 32 codons ϭ 2784). Libraries obtained were analyzed by flow cytometry as described above and sorted with 10 nM MART-1⅐HLA-A2 monomer or 100 nM tetramer or anti-V␤16 (1:100) by FACS. An additional sort was performed with 100 nM tetramer, where yeast cells displaying SCLs were incubated at 45°C for 30 min before treatment with tetramer. The top 1% of cells with bound ligand were collected from each sorted population and expanded at 30°C. Equal numbers of cells from sorted and unsorted libraries were lysed, and DNA was isolated (Zymo Research Corp.). Genomic DNA was removed by treatment with exonuclease I and -exonuclease (New England Biolabs, Inc.), and plasmid DNA was purified. Resulting DNA was subjected to deep sequencing, as described previously (39) . V␣ and V␤ fragments were prepared by PCR for deep sequencing by adding sequences that allow annealing to Illumina MiSeq sequencing primers, followed by adding sequences that allow annealing to flow cell ("adapters"), and allow unique identification of DNA isolated from unsorted or sorted libraries ("indexes"). Amplified PCR products were purified by gel extraction and sequenced using 250-nucleotide paired-end sequencing runs on a MiSeq sequencer. Resulting sequences were analyzed by Enrich software (75, 76) to obtain enrichment ratios for each substitution at library locations compared with the wildtype residue (enrichment ratio ϭ frequency of the substitution in sorted library/frequency of the substitution in unselected library), and sequence fitness landscapes for each sorting condition were created.
Construction and selection of interface libraries in T1 TCR
Like SCL constructed in various regions of T1 TCR during deep mutational scan, additional libraries were constructed at possible interface residues by PCR-based methods as described above. Choice of residues to make interface libraries was guided by deep mutational scans of T1 and structural analysis of existing V␣2-containing TCRs (40, (43) (44) (45) , searching for possible binding partners of each interface residue in a 4-Å space. Based on deep mutational scans and structural analysis, SCL in 5 V␣ residues (Phe 33␣ , Lys 41␣ , Ser 42␣ , Met 97␣ , and Asp 100␣ ) and 11
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V␤ residues (Met 39␤ , Lys 41␤ , Glu 42␤ , Lys 44␤ , Phe 45␤ , Met 60␤ , Phe 91␤ , Val 101␤ , Glu 102␤ , and Gly 106␤ ) were used. Additionally, PCLs were constructed in seven V␣/V␤ pairs (Lys 41␤ /Asp 100␣ , Glu 42␤ /Asp 100␣ , Lys 44␤ /Met 97␣ , Phe 45␤ /Met 97␣ , Phe 91␤ /Lys 41␣ , Phe 91␤ /Ser 42␣ , and Gly 106␤ /Ser 42␣ ). PCR products for SCL were pooled separately from PCL and transformed into yeast. Resultant libraries contained 2 ϫ 10 7 and 5 ϫ 10 7 independent transformants for pooled SCL and PCL, respectively, which exceeded by several orders of magnitude the expected diversity (16 positions ϫ 32 codons ϭ 512 for SCL; 7 ϫ (32 ϫ 32 codons) ϭ 7168 for PCL). Equal numbers of yeast cells displaying SCL or PCL were mixed and sorted by FACS twice with 1 nM MART-1⅐HLA-A2 (with or without prior exposure to pooled normal human serum (supplemented with 10 mM EDTA) at 37°C for 30 min). The top 1% of cells bound to MART-1⅐HLA-A2 were collected, and individual mutants from each sorting condition were isolated that were analyzed by sequencing or flow cytometry as described above.
Binding of soluble T1 and F45␤Y TCRs to MART-1⅐HLA-A2 by ELISA
T1 scTCR and the F45␤Y mutant scTCR were cloned in pET28a for expression in E. coli as inclusion bodies that were refolded as described previously (23) . Soluble, monomeric protein was coated on wells of an ELISA plate (5 g/ml), followed by incubation with various concentrations of MART-1⅐HLA-A2. Bound MART-1⅐HLA-A2 was detected with anti-␤ 2microglobulin antibody conjugated to horseradish peroxidase (Bio-Rad). The addition of 3,3Ј,5,5Ј-tetramethylbenzidine substrate (KPL, Inc.) allowed development of colored product that was detected by measuring absorbance at 450 nm.
Measurement of kinetic parameters of binding of soluble T1 and F45␤Y TCRs to MART-1⅐HLA-A2 by surface plasmon resonance
Biotinylated MART-1⅐HLA-A2 or WT1⅐HLA-A2 was coated on sensor chip CAP (GE Healthcare) mounted on a Biacore 3000 instrument set at 25°C. Soluble, monomeric scTCRs (T1 or F45␤Y) were injected over the coated surface at a flow rate of 30 l/min. All proteins were buffer-exchanged to SPR running buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20). Resulting data were analyzed using Biaevaluation version 4.1 software (55) .
Thermostability assays of T1 and F45␤Y TCRs
Thermostability of T1 and F45␤Y TCRs were measured in yeast-displayed form as well as in soluble form. To measure thermostability in yeast-displayed form, yeast cells displaying T1 or F45␤Y TCR were incubated at temperatures ranging from 30 to 80°C for 30 min and then stained with monomeric, biotinylated MART-1⅐HLA-A2 followed by staining with streptavidin-PE. The percentage decrease in fluorescence relative to fluorescence at 30°C was calculated for each mutant and plotted against temperature to obtain melting curves and T m (46) . To measure thermostability in soluble form, solutions containing soluble monomers of T1 or F45␤Y TCRs (5 M), 5ϫ SyproOrange, and 1ϫ assay buffer were aliquoted into wells of a 384-well plate and exposed to increasing temperature (at a rate of ϳ1°C/min) in a Taqman ABI 7900 real-time PCR instrument. Resulting fluorescence obtained was plotted against temperature using OriginPro software. First derivatives of bi-Gaussian function fitted data were used to precisely calculate T m .
Protein modeling by RosettaBackrub
For protein modeling, we used Mel5 TCR (PDB code 3HG1) (43) as a template and RosettaBackrub (59) (http://kortemmelab. ucsf.edu/backrub) 3 as the modeling tool. Mel5 TCR (like T1) also binds to MART-1⅐HLA-A2 and uses the same V␣ region (TRAV12-2) as T1. For modeling the V␣/V␤ interface of T1 or F45␤Y TCRs, we mutated a stretch of amino acids in Mel5 ( 92 VAGKST 97 in V␣ and 43 LQLLFYS 49 in V␤) to residues in T1 or F45␤Y TCR ( 92 SSDFLM 97 in V␣ and 43 IK(F/Y)LLHF 49 in V␤) (Fig. S1 ). The top scoring models of each were analyzed and overlaid in PyMOL (Schrödinger, LLC).
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